- Lobbying
- Lobbying by Z-Medica Corporation
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Elizabeth Powell | Legislative Director for Rep. Jim Langevin 2001-2002 and Legislative Director for Rep. Juanita Millender-McDonald 1997-2001 |
Rebecca Watts | Appropriations Director for U.S. Senator Mike DeWine, 2000-2006 |
Kaitlyn Brown | Legislative Aide/Legislative Correspondent (2016-2018) |
Katherine Collins | Deputy Director of Operations, The Executive Residence, Executive Office of the President (2011-2016) and Policy Associate, White House Cancer Moonshot Task Force, Office of the Vice President, Executive Office of the President (2016 - 2017) |
John Richter | Legislative Assistant for Rep. Michelle Lujan Grisham (2014-2017) and Legislative Aide/Legislative Correspondent for Sen. Robert P. Casey, Jr. (2010-2014) |
Elizabeth Powell G2G co | Legislative Director for Rep. Jim Langevin 2001-2002 and Legislative Director for Rep. Juanita Millender-McDonald 1997-2001 |
Jeremy D'Aloisio | n/a |
Tyler Allchin | n/a |
Alexandra Fabian | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Registration
Issue(s) they said they’d lobby about: Regarding emergency medical devices.
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Type of Issue
Termination
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Defense - Dept of (DOD)
Army - Dept of (Other)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Defense - Dept of (DOD)
Army - Dept of (Other)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Defense
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Defense - Dept of (DOD)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Defense - Dept of (DOD)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Defense - Dept of (DOD)
Homeland Security - Dept of (DHS)
Army - Dept of (Other)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Defense - Dept of (DOD)
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Defense - Dept of (DOD)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Defense - Dept of (DOD)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Defense - Dept of (DOD)
Type of Issue
Registration
Issue(s) they said they’d lobby about: Defense, medical research and development.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate